The Retina Channel Podcast – Details, episodes & analysis

Dr. Marc Spirn from Wills Eye Hospital discusses the results of a retrospective study of performing lattice degeneration on a series of patients who had lattice degeneration with high risk features.

The discussed article:

Kazan AS, Mahmoudzadeh R, Salabati M, Sharpe J, Fineman MS, Hsu J, Yonekawa Y, Spirn MJ. Indications and Outcomes of Laser Retinopexy in Eyes With High-Risk Lattice Degeneration. J Vitreoretin Dis. 2024 Apr 25;8(4):381-387. doi: 10.1177/24741264241248253. PMID: 39148566; PMCID: PMC11323511.

Dr. Witkin from the American Society of Retina Specialists talks about our current knowledge of the incidence of retinal vasculitis following intravitreal injection of Pegcetacoplan for treatment of geographic atrophy.

Discussed article:

Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis. 2023 Dec 21;8(1):9-20. doi: 10.1177/24741264231220224. Erratum in: J Vitreoretin Dis. 2024 Feb 29;8(3):363. doi: 10.1177/24741264241238212. PMID: 38223782; PMCID: PMC10786078.

Prof. Gemmy Cheung from the National University of Singapore and Singapore National Eye Center discusses her research results on progression of Geographic Atrophy on Asian vs non-Asian Eyes.

References Article:

Teo KYC, Fujimoto S, Sadda SR, Kokame G, Gomi F, Kim JE, Cheng MFS, Corradetti G, Amornpetchsathaporn A, Chainakul M, Lee WK, Lai TYY, Ruamviboonsuk P, Cheung CMG. Geographic Atrophy Phenotypes in Subjects of Different Ethnicity: Asia-Pacific Ocular Imaging Society Work Group Report 3. Ophthalmol Retina. 2023 Jul;7(7):593-604. doi: 10.1016/j.oret.2022.12.013. Epub 2022 Dec 28. PMID: 36586466.

Dr. Regillo describes the results of the phase 3 prospective study of Ranibizumab Port Delivery System (PDS) for the treatment of neovascular AMD. 

Reference Article:

Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2. PMID: 36870451.

Dr. Smiddy presents a cost analysis of the step therapy for treatment of diabetic macular edema based on DRCR protocol AC results.

Discussed article:

Patel NA, Al-Khersan H, Yannuzzi NA, Lin J, Smiddy WE. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results. Ophthalmol Retina. 2023 May;7(5):413-419. doi: 10.1016/j.oret.2022.11.010. Epub 2022 Nov 22. PMID: 36423893.

Dr. Jason Hsu from Wills Eye Hospital returns to The Retina Channel to discuss his groups' retrospective study of eyes with advanced retinal detachement (PVR grade C or worse) that underwent retinectomy without lensectomy. Their study showed that 75% of these eyes at 3 months (and 68% at 6 months) had single surgery anatomic success. The study is suggestive that lensectomy and even peripheral vitreous base sheving may not be necessary when doing retinectomy for advanced RD cases. 

Full reference to the article:

Mahmoudzadeh R, Mokhashi N, Anderson H, Patel S, Salabati M, Chiang A, Kuriyan AE, Gupta OP, Mehta S, Garg SJ, Hsu J. Outcomes of Retinectomy without Lensectomy in Rhegmatogenous Retinal Detachments with Proliferative Vitreoretinopathy. Ophthalmol Retina. 2023 Jan;7(1):52-58. doi: 10.1016/j.oret.2022.07.008. Epub 2022 Aug 5. PMID: 35940476.

Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD. 

Dr. Noemi Lois from Queens University in Belfast, UK discusses results of the DIAMONDS study, which was a prospective trial that looked into the effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 um.

Referenced article:

Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon G, Saad A, Sivaprasad S, Shiew M, Steel DH, Talks JS, Doherty P, McDowell C, Clarke M; DIAMONDS Study Group. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial. Ophthalmology. 2023 Jan;130(1):14-27. doi: 10.1016/j.ophtha.2022.08.012. Epub 2022 Aug 13. PMID: 35973593.

Dr. Xuejing Chen discusses her group's retrospective analysis of the incidence and risk factors of delayed retinal breaks following a symptomatic posterior vitreous detachment.

Discussed article:

Jindachomthong KK, Cabral H, Subramanian ML, Ness S, Siegel NH, Chhablani J, Hsu SX, Chen X. Incidence and risk factors for delayed retinal tears following an acute, symptomatic posterior vitreous detachment. Ophthalmol Retina. 2022 Oct 25:S2468-6530(22)00514-0. doi: 10.1016/j.oret.2022.10.012. Epub ahead of print. PMID: 36307014.

Dr. Jhavery discusses results of DRCR Retina Protocol AC study which compared DME response to anti-VEGF injections in patients who received Aflibercept monotherapy vs those who started with Bevacizumab first and then switched to Aflibercept if needed. 

Discussed article:

Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. PMID: 35833805.